搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
The Edge Singapore
2 小时
Panellists at MooSummit 2024 identify interesting investing themes
Older Singapore investors can opt for ETFs in Singapore dollars (SGD) listed on the Singapore Exchange S68 The MooSummit took ...
4 小时
Ozempic could help with opioid and alcohol abuse, new research shows
Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.
来自MSN
6 小时
Lilly Loses Around $14B This Week: How to Play LLY Stock
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.
The National
7 小时
Labour plans will make Big Pharma happy but ignore problem’s roots
PRIVATE healthcare errand boy Wes Streeting has hit the streets running. His magic bullet for getting overweight people back to work is to ...
9 小时
Ozempic and other weight loss drugs could help treat alcohol and drug addiction, study says
The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.
9 小时
2 High-Flying Growth Stocks With Massive Upside Potential
The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...
13 小时
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR
Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...
13 小时
This is Huge News For Eli Lilly Investors
Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...
ConsumerAffairs
1 天
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Health.com
1 天
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
1 天
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
HealthLeaders Media
1 天
Healthy Returns: Covering weight loss drugs could cost Medicare $35B through 2034
Those include GLP-1s for obesity such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which both carry hefty price tags of roughly $1,000 per month before insurance and other rebates.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈